Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cellectar Biosciences, Inc. on July 15, 2016. The filing reports the appointment of a new senior executive officer effective July 15, 2016, and references a press release issued on July 20, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Jarrod Longcor as Senior Vice President of Corporate Development and Operations. Mr. Longcor brings over 20 years of pharmaceutical and biotech experience, including previous roles as Chief Business Officer at Avillion LLP and Vice President of Corporate Development at Rib-X Pharmaceuticals.
Management Commentary and Compensation
Management has outlined the following compensatory arrangements for Mr. Longcor:
- Base Salary: $285,000 per year.
- Annual Bonus: Targeted at 30% of base salary.
- Equity Grant: An inducement award of options to purchase 75,000 shares of common stock at an exercise price of $2.93 per share, vesting quarterly over three years.
- Severance: Entitled to six months of severance in the event of dismissal without cause or constructive dismissal following a change in control.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 75,000 stock options granted to Mr. Longcor.
- Confirm the total potential annual compensation including the targeted bonus.
- Review the referenced press release (Exhibit 99.1) for additional strategic context regarding the appointment.
- Check subsequent filings for any impact on the company's cash burn rate due to the new executive salary.